Litcius/Paper detail

Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells

Dwight H. Owen, Brooke Benner, Carly Pilcher, Logan Good, Himanshu Savardekar, Ruthann Norman, Christian Ghattas, Manisha H. Shah, Bhavana Konda, Claire F. Verschraegen, Robert Wesolowski, Gregory K. Behbehani, William E. Carson, Gregory A. Otterson

2020Clinical Lung Cancer12 citationsDOIOpen Access PDF

Topics & Concepts

NivolumabMedicineTemozolomideLung cancerOncologyBiomarkerMyeloidClinical trialCancer researchInternal medicineCancerImmunotherapyChemotherapyBiologyBiochemistryLung Cancer Research StudiesCancer therapeutics and mechanismsPeptidase Inhibition and Analysis
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells | Litcius